The announcement marks the next step in Johnson & Johnson's South African journey. Under a single umbrella, the company plans to further leverage its expertise in innovative medicine and medical technology to treat complex diseases and introduce solutions that deliver smarter, less invasive and more personalised patient care, says the brand. 

Moving forward, the company's two segments will be more connected to the Johnson & Johnson brand. Janssen, the company's pharmaceutical segment, will henceforth be known as Johnson & Johnson Innovative Medicine. The medical technology segment will continue to be known as Johnson & Johnson MedTech. The changes form part of a global rollout of the new Johnson & Johnson brand, first announced in September 2023, adds the brand.

Ahmed El Hofy, General Manager at Johnson & Johnson Innovative Medicine South Africa says, "We are excited to enter a new era of healthcare innovation and tackling the toughest health challenges. Though our name has changed, our purpose remains the same. We will continue to focus on developing innovative treatments and championing patients every step of the way, while staying true to our credo values. We remain committed to serving patients, healthcare providers and communities in South Africa and beyond."

Johnson & Johnson concludes that the new Johnson & Johnson brand identity builds on the company's legacy, while also modernising key elements to showcase healthcare innovation in a way that’s inclusive and brings the company's warm, caring nature to life. 

For more information, visit www.jnj.com. You can also follow Johnson & Johnson on Facebook, LinkedIn, or on X. 

*Image courtesy of contributor